DIVISLAB Divi's Laboratories Q3 FY25 results (Oct–Dec 2024) and concall
Divi's delivered a strong Q3 with 25% revenue growth and 64% PAT growth driven by custom synthesis momentum (53% of Q3 revenue). EBITDA margins expanded to ~32% on favorable product mix and operating leverage. Kakinada Phase 1 commenced in January 2025 for backward integration and starting materials. Management actively engaging with innovators on GLP-1 building blocks, fragments and peptide synthesis using both SPPS and LPPS capabilities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 2,302 | 2,297 |
| EBITDA | 729 | 747 |
| Net profit | 518 | 594 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
